Leading products shifting generations, ‘Sovaldi’ & ‘Daklinza’
The Korean outpatient prescription market is experiencing a shift in generations. Raising positions in the ranking, Gilead Sciences’ hepatitis C treatment ‘Sovaldi’ and BMS’s ‘Daklinza’ have taken the leading roles in the phenomenon.
On the other hand, BMS’s hepatitis B treatment ‘Baraclude’ and...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
